- B2C
- Early StageStartup in initial stages
Curelator careers
Curelator’s digital platform helps individuals suffering from diseases with debilitating, episodic attacks to identify, predict and control the complex array of factors that trigger their attacks.
Our first product, Curelator Headache™ targets 70 million migraine sufferers. It requires daily data entry from the patient and generates an Individual Trigger Map™ for each user that allows them to identify the migraine triggers that cause their attacks and dismiss supposed triggers that are unimportant. Migraine Predictor™ will anticipate both disease free and migraine days in users and with the latter directs users to take positive steps to avoid a disabling headache and improve health outcomes.
“The Curelator approach is unique in that it is specifically designed to allow migraine patients to identify and manage the factors that influence day to day variation in their risk of attacks.”
Richard B. Lipton, M.D. Director Montefiore Headache Center, Member Clinical Advisory Board Curelator
Our first product, Curelator Headache™ targets 70 million migraine sufferers. It requires daily data entry from the patient and generates an Individual Trigger Map™ for each user that allows them to identify the migraine triggers that cause their attacks and dismiss supposed triggers that are unimportant. Migraine Predictor™ will anticipate both disease free and migraine days in users and with the latter directs users to take positive steps to avoid a disabling headache and improve health outcomes.
“The Curelator approach is unique in that it is specifically designed to allow migraine patients to identify and manage the factors that influence day to day variation in their risk of attacks.”
Richard B. Lipton, M.D. Director Montefiore Headache Center, Member Clinical Advisory Board Curelator
Curelator hasn't added any jobs yet
Get notified when Curelator posts new jobs.
Alec Mian
CEO Gamera Biosciences: 1993 (sold to Tecan) Genmedica Therapeutics (currently in phase 2 clinical trials) in 2005. PhD in Genetics Cambridge, UK & Harvard, USA
RF Venue • Walpole • 3 days ago
ClassPass • New York City • $151k – $200k • 2 weeks ago
MoodMe • New York City • 10.0% – 25.0% • 3 weeks ago
Acquia • Boston • $145k – $158k • 3 weeks ago

